Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lisata Therapeutics (LSTA) Deferred Taxes (2016 - 2017)

Lisata Therapeutics' Deferred Taxes history spans 8 years, with the latest figure at -$49531.0 for Q1 2017.

  • For Q1 2017, Deferred Taxes rose 7.21% year-over-year to -$49531.0; the TTM value through Mar 2017 reached $3847.0, down 99.98%, while the annual FY2017 figure was -$575000.0, N/A changed from the prior year.
  • Deferred Taxes reached -$49531.0 in Q1 2017 per LSTA's latest filing, down from $147286.0 in the prior quarter.
  • In the past five years, Deferred Taxes ranged from a high of $13.6 million in Q4 2015 to a low of -$447568.0 in Q2 2013.
  • Average Deferred Taxes over 5 years is $1.1 million, with a median of -$46793.5 recorded in 2015.
  • Peak YoY movement for Deferred Taxes: plummeted 263.95% in 2013, then skyrocketed 7915.15% in 2015.
  • A 5-year view of Deferred Taxes shows it stood at -$287779.0 in 2013, then surged by 185.62% to $246385.0 in 2014, then soared by 5433.39% to $13.6 million in 2015, then plummeted by 98.92% to $147286.0 in 2016, then tumbled by 133.63% to -$49531.0 in 2017.
  • Per Business Quant, the three most recent readings for LSTA's Deferred Taxes are -$49531.0 (Q1 2017), $147286.0 (Q4 2016), and -$46954.0 (Q3 2016).